Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Int J Infect Dis. 2013 Dec;17(12):e1116-20. doi: 10.1016/j.ijid.2013.06.006. Epub 2013 Aug 2.
Previous treatment has been documented as a major risk factor for multidrug-resistant tuberculosis (MDR-TB). However, risk factors for MDR-TB among previously treated patients in China are unclear. This study aimed to ascertain the risk factors for MDR-TB in this particular population in China.
A case-control study was conducted from July through August 2011 in five cities of Zhejiang Province. Cases were previously treated TB patients who had disease resistant to at least isoniazid and rifampin, whereas controls were previously treated TB patients who had disease sensitive to isoniazid and rifampin.
Ninety-eight cases and 83 controls were identified. Multivariate analysis showed that a duration of first treatment of more than 8 months (odds ratio (OR) 2.18, 95% confidence interval (CI) 1.05-4.52), more than three prior episodes of anti-TB treatment (more than 2 months of continuous treatment as one episode) (OR 5.57, 95% CI 2.38-13.00), adverse effects of anti-TB medication (OR 3.63, 95% CI 1.79-7.36), and more than three TB foci in the lung (OR 2.17, 95% CI 1.08-4.37) were associated with MDR-TB in previously treated TB patients. Low family income (p=0.056) was marginally significant in the univariate analysis.
Particular clinical diagnostic results, such as more than three TB foci in the lung, non-standard or irregular therapy, and adverse effects of anti-TB medication, were found to be associated with MDR-TB in previously treated TB patients. High quality directly observed treatment should be strengthened to ensure that the previously treated patients can receive standard and regular regimens.
既往治疗史是耐多药结核病(MDR-TB)的一个主要危险因素。然而,中国既往治疗患者发生 MDR-TB 的危险因素尚不清楚。本研究旨在确定中国这一特定人群中 MDR-TB 的危险因素。
2011 年 7 月至 8 月在浙江省 5 个城市进行了一项病例对照研究。病例为至少对异烟肼和利福平耐药的既往治疗结核病患者,而对照为对异烟肼和利福平敏感的既往治疗结核病患者。
共确定了 98 例病例和 83 例对照。多因素分析显示,首次治疗持续时间超过 8 个月(比值比(OR)2.18,95%置信区间(CI)1.05-4.52)、既往抗结核治疗次数超过 3 次(超过 2 个月的连续治疗作为一次)(OR 5.57,95% CI 2.38-13.00)、抗结核药物不良反应(OR 3.63,95% CI 1.79-7.36)和肺部结核病灶超过 3 个(OR 2.17,95% CI 1.08-4.37)与既往治疗结核病患者发生 MDR-TB 相关。家庭收入低(p=0.056)在单因素分析中具有显著意义。
肺部结核病灶超过 3 个、非标准或不规则治疗以及抗结核药物不良反应等特定临床诊断结果与既往治疗结核病患者的 MDR-TB 相关。应加强高质量的直接观察治疗,确保既往治疗患者接受标准和规范的治疗方案。